Intravenous tPA (Tissue-Type Plasminogen Activator) in Patients With Acute Ischemic Stroke Taking Non–Vitamin K Antagonist Oral Anticoagulants Preceding Stroke Ying Xian 10.25376/hra.8089310.v1 https://hra.figshare.com/articles/preprint/Intravenous_tPA_Tissue-Type_Plasminogen_Activator_in_Patients_With_Acute_Ischemic_Stroke_Taking_Non_Vitamin_K_Antagonist_Oral_Anticoagulants_Preceding_Stroke/8089310 <div>These preliminary observations suggest that tPA may be reasonably well tolerated without prohibitive risks of bleeding complications in selected patients on NOACs. Reversal of anticoagulant effects by idarucizumab for dabigatran-treated patients before tPA is an emerging strategy that was associated with more favorable outcomes</div> 2019-05-07 15:00:03 apixaban dabigatran intracranial hemorrhages rivaroxaban stroke Cardiology (incl. Cardiovascular Diseases)